Kaur Inderjeet, Dogra Sunil, Narang Tarun, De Dipankar
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Australas J Dermatol. 2009 Aug;50(3):181-5. doi: 10.1111/j.1440-0960.2009.00534.x.
The present study was undertaken to compare the efficacy and safety of thalidomide to that of oral prednisolone in the treatment of moderate to severe type 2 lepra reaction. Sixty patients with a histologically confirmed diagnosis of erythema nodosum leprosum with a clinical score of 4 or more (i.e. moderate to severe type 2 reaction) were randomly allocated to two groups comprising 30 patients each. Group 1 patients were given thalidomide at a dose of 300 mg/day for 1 week and the dose was gradually reduced, and Group 2 received prednisolone 40 mg daily for 2 weeks, which was tapered by 10 mg every 2 weeks. Thalidomide induced a faster clinical response (cutaneous as well as systemic) compared with prednisolone. Patients taking thalidomide had fewer relapses and a longer period of remission than those receiving prednisolone.
本研究旨在比较沙利度胺与口服泼尼松龙治疗中度至重度2型麻风反应的疗效和安全性。60例经组织学确诊为结节性红斑麻风且临床评分4分或更高（即中度至重度2型反应）的患者被随机分为两组，每组30例。第1组患者给予沙利度胺，剂量为300mg/天，持续1周，然后逐渐减量；第2组患者接受泼尼松龙40mg/天，持续2周，每2周减量10mg。与泼尼松龙相比，沙利度胺诱导的临床反应（皮肤及全身）更快。服用沙利度胺的患者比接受泼尼松龙的患者复发更少，缓解期更长。
